Stocks Hitting 52-Week Lows

shares touched a new 52-week low of $0.381 following a business update. Peregrine announced after Thursday's market close that it will discontinue the ongoing Phase III SUNRISE trial of bavituximab in patients with previously treated cell lung cancer.

shares fell 36.32 percent to reach a new 52-week low of $4.40 after the company placed its CLIN3001 Postoperative Pain Trial for I.V. CR845 on hold pending safety review.

shares touched a new 52-week low of $22.44. PharMerica reported Q4 earnings of $0.45 per share on revenue of $520.6 million.

shares touched a new 52-week low of $21.151. PRA Group reported Q4 earnings of $1.03 per share on sales of $230.2 million.